Literature DB >> 14522928

Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.

Kazuyuki Kawakami1, Go Watanabe.   

Abstract

The variable number of tandem repeat (VNTR) of thymidylate synthase (TS) gene, mainly 2 repeat (2R) and 3 repeat (3R), is one of the genetic variations that can potentially predict the effectiveness of 5-fluorouracil-based chemotherapy. In this study we identified an additional single nucleotide polymorphism (SNP) in the VNTR of TS, followed by functional and clinical analysis of the SNP. Two-hundred fifty eight tumor samples were obtained from patients with primary colorectal adenocarcinoma. We observed three different patterns of electrophoresis by analysis of the VNTR with 2R/3R heterozygote. The sequencing results revealed a SNP, G/C polymorphism, within the 28-bp repeat component of TS VNTR. Each polymorphic allele was assigned as 2G, 2C, 3G, or 3C according to the combination of SNP and VNTR. Functional analysis showed that the plasmid construct with 3G sequence had three to four times greater efficiency of translation than other polymorphic sequences. 3R allele in colorectal cancer was subdivided into around half by the SNP, indicating its commonness among Japanese. TS genotypes of the patients with colorectal cancer were classified into high expression type (2R/3G, 3C/3G, and 3G/3G) and low expression type (2R/2R, 2R/3C, and 3C/3C). The patients who received oral fluoropyrimedines survived longer than the patients with no treatment in the group of low expression type. No benefit of oral fluoropyrimedines was observed in the group of high expression type. These results suggest that the double polymorphism in the TS tandem repeat sequence, the SNP and the VNTR, may provide a potential for more effective prediction of the clinical outcome of 5-fluorouracil-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522928

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; M J E M Gosens; E Moerland; I van Lijnschoten; V E P P Lemmens; G D Slooter; H J T Rutten; Adriaan J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-06-01       Impact factor: 6.730

Review 2.  Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

Authors:  Norman H Lee
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

Review 3.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

4.  Modern origin of numerous alternatively spliced human introns from tandem arrays.

Authors:  Degen Zhuo; Richard Madden; Sherif Abou Elela; Benoit Chabot
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

5.  Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.

Authors:  Pere Domingo; M Carmen Cabeza; Alain Pruvost; Ferran Torres; Juliana Salazar; M del Mar Gutierrez; M Gracia Mateo; Angels Fontanet; Irene Fernandez; Joan C Domingo; Francesc Villarroya; Francesc Vidal; Montserrat Baiget
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.

Authors:  Soma Ghosh; Jordan M Winter; Kalpesh Patel; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

7.  Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.

Authors:  Shenli Zhang; Iain B Tan; Nur S Sapari; Heike I Grabsch; Alicia Okines; Elizabeth C Smyth; Toru Aoyama; Lindsay C Hewitt; Imran Inam; Dan Bottomley; Matthew Nankivell; Sally P Stenning; David Cunningham; Andrew Wotherspoon; Akira Tsuburaya; Takaki Yoshikawa; Richie Soong; Patrick Tan
Journal:  J Mol Diagn       Date:  2015-03-04       Impact factor: 5.568

Review 8.  Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.

Authors:  M Gusella; E Pezzolo; Y Modena; C Barile; D Menon; G Crepaldi; F La Russa; A P Fraccon; F Pasini
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

9.  Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Aurea Lima; Vítor Seabra; Sandra Martins; Ana Coelho; António Araújo; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

10.  Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.

Authors:  R Zarate; J Rodríguez; E Bandres; A Patiño-Garcia; M Ponz-Sarvise; A Viudez; N Ramirez; N Bitarte; A Chopitea; J Gacía-Foncillas
Journal:  Br J Cancer       Date:  2010-03-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.